The Kantaro COVID-SeroKlir SARS-CoV-2 IgG antibody test from EKF Diagnostics is one of the first to detect both the presence and precise levels of COVID-19 neutralising antibodies. Click to read more.
Pfizer, Moderna, Astrazeneca, Bharat Biotech, other COVID-19 vaccines in use or getting close
The shots were all tested differently, and some were allowed to go into use even before they were rigorously tested.
Feb 01, 2021 15:25:05 IST
While a few have already hit the market, there are still dozens of coronavirus vaccines in development around the globe. Some use tried-and-true technologies, other use novel approaches. The shots were all tested differently, and some were allowed to go into use even before they were rigorously tested. How well they work varies, with preliminary study results ranging from 50% effective to over 90%. So far, regulators in different countries have allowed use of about a half dozen, mostly under emergency use provisions. A few more are getting close. The ones available now all require two doses, given weeks apart.
Research Article
Healthy lifestyle, endoscopic screening, and colorectal cancer incidence and mortality in the United States: A nationwide cohort study
Kai Wang, Roles Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Project administration, Resources, Software, Validation, Visualization, Writing – original draft, Writing – review & editing
Affiliation Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, United States of America Roles Formal analysis, Methodology, Project administration, Software, Writing – review & editing
Affiliations Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States of America, Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States of America
The day a muddled mob stormed the US Capitol building, a team of American researchers published a paper in Nature that signified a landmark in gene therapy.
The head of the US National Institutes of Health, Francis Collins had joined forces with Harvard University professor David Liu and others to tackle progeria, a genetic disorder that causes children to age rapidly.
The achievement, successfully tested in mice, was made possible by Liu’s invention of a second-generation CRISPR gene-editing technology called “base editing”. With this, researchers may eventually be able to correct lifelong genetic diseases, including progeria, in humans.
A rare but devastating disease